NCT03989167 Clinical Decision Support for Familial Hypercholesterolemia
| NCT ID | NCT03989167 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Linkoeping |
| Condition | Hypercholesterolemia, Familial |
| Study Type | INTERVENTIONAL |
| Enrollment | 460,000 participants |
| Start Date | 2022-12-06 |
| Primary Completion | 2025-12-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 460,000 participants in total. It began in 2022-12-06 with a primary completion date of 2025-12-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A cluster randomized study in the primary care setting to evaluate a computer-based clinical decision support system to aid in the identification and management of patients with FH. The primary outcome of the study is the number of patients diagnosed with FH thirty-six months after study initiation.
Eligibility Criteria
Inclusion Criteria * Primary care centers in the county of Östergötland. Exclusion Criteria * Primary care centers not using the Cambio Cosmic Electronic Health Record System.
Contact & Investigator
Lars O Karlsson, MD, PhD
PRINCIPAL INVESTIGATOR
Linkoping University. Linkoping University Hospital
Frequently Asked Questions
Who can join the NCT03989167 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hypercholesterolemia, Familial. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03989167 currently recruiting?
Yes, NCT03989167 is actively recruiting participants. Contact the research team at lars.o.karlsson@regionostergotland.se for enrollment information.
Where is the NCT03989167 trial being conducted?
This trial is being conducted at Linköping, Sweden.
Who is sponsoring the NCT03989167 clinical trial?
NCT03989167 is sponsored by University Hospital, Linkoeping. The principal investigator is Lars O Karlsson, MD, PhD at Linkoping University. Linkoping University Hospital. The trial plans to enroll 460,000 participants.